Acrux (ARUXF) PE Ratio: At Loss (As of Jun. 26, 2026)


What is Acrux PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-26), Acrux's share price is $0.0169. Acrux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00. Therefore, Acrux's PE Ratio for today is At Loss.

During the past 13 years, Acrux's highest PE Ratio was 10.52. The lowest was 0.00. And the median was 4.04.

Acrux's EPS (Diluted) for the six months ended in Dec. 2025 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.

As of today (2026-06-26), Acrux's share price is $0.0169. Acrux's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00. Therefore, Acrux's PE Ratio without NRI ratio for today is At Loss.

During the past 13 years, Acrux's highest PE Ratio without NRI was 10.52. The lowest was 0.00. And the median was 3.95.

Acrux's EPS without NRI for the six months ended in Dec. 2025 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 21.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.20% per year.

During the past 13 years, Acrux's highest 3-Year average EPS without NRI Growth Rate was 67.30% per year. The lowest was -47.30% per year. And the median was 11.20% per year.

Acrux's EPS (Basic) for the six months ended in Dec. 2025 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.

Back to Basics: PE Ratio


Acrux  (OTCPK:ARUXF) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Acrux PE Ratio Related Terms


Acrux PE Ratio Historical Data

* Premium members only.

The historical data trend for Acrux's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrux PE Ratio Chart

Acrux Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Acrux Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

ARUXF vs VRTX, REGN, ALNY: PE Ratio Comparison

For the Biotechnology subindustry, Acrux's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acrux PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's PE Ratio distribution charts can be found below:

* The bar in red indicates where Acrux's PE Ratio falls into.


Acrux PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Acrux's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.0169/-0.004
=-4.23(At Loss)

Acrux's Share Price of today is $0.0169.
For company reported semi-annually, Acrux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Acrux Business Description

Other Exchanges FJY:GermanyACR:Australia
Address 103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.